NEW YORK (GenomeWeb) – When Abbott recently received a CE mark for its most advanced point-of-care instrument, the milestone initiated an inaugural product launch from within a portfolio of next-generation Dx instruments that will soon be available to customers, the firm said.

The instruments are part of Abbott's Alinity family, which consists of diagnostic instruments and tests within the firm's point-of-care, immunoassay, clinical chemistry, hematology, blood and plasma screening, and molecular diagnostics product segments.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Sponsored by

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.